help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bahn, R. S.
Right arrow Articles by Gorman, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bahn, R. S.
Right arrow Articles by Gorman, C. A.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 559-563, Copyright © 1990 by Endocrine Society

ARTICLES

Clinical review 13: Diagnosis and management of Graves' ophthalmopathy

RS Bahn, JA Garrity and CA Gorman
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.

Although Graves ophthalmopathy is a potentially sight threatening and disfiguring condition that can be frightening for the patient to experience, there are effective means of management. At the present time, treatment is based on the relief of excessive intraorbital pressures and is accomplished either by shrinking the orbital contents or by expanding the orbital volume. The most effective treatment modality or combination of modalities is an area of controversy. However, it must be remembered that the approach to management undertaken should be finely tuned to the needs of the particular individual afflicted with the condition. Perhaps with a greater understanding of pathophysiology, more reliable and effective treatments, based on specific pathophysiological mechanisms, may be developed. In addition, tests to reliably predict those patients most likely to progress in their disease might be developed, allowing preventive measures to be taken.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
G. J. Kahaly, H.-P. Rösler, S. Pitz, and G. Hommel
Low- Versus High-Dose Radiotherapy for Graves' Ophthalmopathy: A Randomized, Single Blind Trial
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 102 - 108.
[Abstract] [Full Text]

Home page
 Br. J. Ophthalmol.Home page
M. A Burnstine, S. G Elner, and V. M Elner
Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A
Br. J. Ophthalmol., March 1, 1998; 82(3): 318 - 322.
[Abstract] [Full Text]

Home page
 NEJMHome page
R. S. Bahn and A. E. Heufelder
Pathogenesis of Graves' Ophthalmopathy
N. Engl. J. Med., November 11, 1993; 329(20): 1468 - 1475.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society